Wesam Medical Holding, a Saudi healthcare investment company, has announced the signing of a strategic Memorandum of Understanding (MOU) with McLaren Health Care, one of the largest healthcare systems in the state of Michigan, United States, and operator of the Karmanos Cancer Institute, to establish a specialized hematology and oncology hospital in Riyadh.
Under the terms of the MOU, Wesam Medical Holding will oversee all legal, regulatory, and local market operations, while McLaren Health Care will be responsible for clinical, operational, and technical components, including hospital design and construction.
This partnership marks a significant milestone in Saudi Arabia’s healthcare sector, representing McLaren’s entry into the Kingdom to provide comprehensive, integrated services for hematology and oncology patients. The collaboration will extend the reach of the system’s renowned Karmanos Cancer Institute, designated by the U.S. National Cancer Institute as a Comprehensive Cancer Center.
The MOU was signed by Mr. Fahad Ibrahim Al-Khalaf, Chairman of Wesam Medical Holding Company, and Dr. Barton Buxton, President and Chief Executive Officer of McLaren Health Management Group, a subsidiary of McLaren Health Care. The partnership aims to transform oncology services in the Kingdom, aligning with the objectives of the Health Sector
inal confirmation of attendees].
Objectives of the Memorandum and Added Value for Healthcare Transformation
The hospital represents the first standalone private comprehensive cancer center in the Kingdom, delivering fully integrated services across hematology and oncology disciplines. It provides high-quality care through Saudi consultants and a multidisciplinary team of highly qualified professionals.
The partnership with McLaren Health Care reflects a shared vision to advance clinical excellence, adopt state-of-the-art technologies, and apply internationally recognized best practices in cancer care and precision medicine.
Prior to signing this memorandum, Wesam Medical conducted a detailed feasibility study for the establishment of the hospital in collaboration with a specialized healthcare consulting firm.
The hospital’s key strategic objectives and pillars include:
Meeting the rising demand for specialized oncology services:
Addressing the growing need for high-quality hematology and oncology care through the private sector, reducing the burden on government-run referral hospitals, and ensuring access to world-class care within the Kingdom.
Leveraging McLaren’s expertise:
Bringing the clinical and operational excellence of McLaren Health Care and its subsidiary, the Karmanos Cancer Institute, one of the leading oncology and research institutions in the United States, to strengthen clinical research and national disease registries in Saudi Arabia.
Enhancing national workforce efficiency:
Providing advanced training and professional development for Saudi physicians, nurses, and administrative personnel through knowledge transfer from McLaren and Karmanos experts, thereby improving the overall quality of healthcare services in the Kingdom.
Transferring American knowledge and technology:
Ensuring the delivery of diagnostic and therapeutic services that meet the highest international standards and align with the Kingdom’s vision for medical innovation and sustainability.
Official Statements
Mr. Fahad Ibrahim Al-Khalaf, Chairman of Wesam Medical Holding Company, stated:
“This partnership represents an important milestone in realizing our investment vision, which focuses on long-term strategic ventures that add sustainable value to the Kingdom’s healthcare sector. Following the completion of the feasibility study for the hematology and oncology hospital, we are pleased to launch this ambitious project in collaboration with McLaren Health Care, a system recognized globally for its excellence in oncology. Together, we will integrate our local expertise with McLaren’s clinical and technical capabilities to deliver specialized healthcare services of the highest international standards.”
Dr. Barton Buxton, President and CEO of McLaren Health Management Group, commented:
“Our collaboration with Wesam Medical Holding marks a significant step in McLaren Health Care’s global strategy. Through this partnership, we aim to extend our mission of delivering value-based healthcare through clinical excellence and cost efficiency beyond the United States. Wesam Medical’s deep understanding of the Saudi healthcare landscape makes it an ideal partner. Together, we will integrate Karmanos Cancer Institute’s world-class oncology standards into the Kingdom’s healthcare system, beginning with Riyadh.”
